Development and validation of an HPLC‐UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV‐positive patients

摘要: Therapeutic drug monitoring may be crucial in selected clinical conditions for the management of HIV infection. In recent years, new antiretrovirals have been introduced and particular elvitegravir (EVG) is now recommended first-line simplification treatment as well dolutegravir (DTG) rilpivirine (RPV). The aim this study was to develop validate a high-performance liquid chromatography-ultraviolet (HPLC-UV) method determining EVG DTG RPV human plasma. Solid-phase extraction applied 600 μL plasma sample. Chromatographic separation three drugs internal standard achieved with gradient acetonitrile phosphate buffer on C18 reverse-phase analytical column 20 min run time. were detected at 265 nm 290 nm. Mean intra- inter-day precisions were  0.997 all drugs. This allows EVG, HIV-positive patients using HPLC-UV.